Oncology Central

Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer

0

Emergence of aggressive prostate cancer (PCa) phenotypes resistant to current available therapies is a significant clinical problem, and novel therapeutic strategies are urgently required. Androgen receptor (AR) action is a key mediator underlying development and progression of PCa. For this reason, androgen deprivation therapy has been a primary standard of care for men for over 70 years with symptomatic, advanced PCa [1]. Unfortunately, ensuing resistance to therapy is inevitable, and men will eventually develop castration-resistant PCa (CRPC).

To view restricted content, please:
Share:

Leave A Comment